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ABSTRACT 36 
Background and aims. Two prospective  randmonised trials,  comparing neoadjuvant 37 
chemotherapy (NACT) with upfront debulking surgery (UDS) in advanced ovarian cancer 38 
(EORTC 55971 and MRC CHORUS)  had  a pre-planned meta-analysis arranged, to examine 39 
the long term outcomes of the trials, and identify any preferable therapeutic  approaches for 40 
subgroup populations. 41 
Methods. The data from both trials were merged with a database lock for the EORTC study 42 
on  June 6th , 2015 and CHORUS May 20th, 2015. The  analysis was undertaken by the EORTC 43 
statistical Team.  44 
Results. 1220 women were randomised. The overall  median follow-up was 7.6 years (EORTC 45 
9.2 and CHORUS 5.9 years). Median age was 63 years (range 25-88 years)  and median size of 46 
the largest metastatic tumour at diagnosis was 8 cm (range 0-50 cm ). FIGO Stage  47 
distribution  was II-IIIB (4.5%), IIIC (68.1%), IV (18.9%) with 8.5% of data missing. Median 48 
overall survival (OS)  for EORTC and CHORUS was significantly different at  2.5 and 2.0 years 49 
respectively,  (p=0.004). When combined, there was  no statistically significant difference 50 
regarding the  median progression-free survival (PFS) ,  at 0.9 and 1 year, UDS and NACT or 51 
OS at  2.2 and 2.3 years respectively. Women with Stage IV disease had a significantly better 52 
PFS and OS with NACT compared with UDS (HR: 0.77 and 0.76; both, p=0.050 and 0.048). 53 
However, in women  with stage IIIC with metastatic tumours at diagnosis ≤ 5cm, PFS was 54 
significantly prolonged with UDS (HR:1.34 and HR:1.26; p = 0.02),without significantly 55 
impacting on OS. 56 
Conclusion. Long term follow-up data in this meta-analysis confirm that NACT and UDS 57 
result in similar PFS and OS in advanced ovarian cancer. However, women with stage IV 58 
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disease had a better OS and PFS with NACT while women with stage IIIC with metastases ≤ 5 59 
cm had a better PFS with UDS.  60 
  61 
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INTRODUCTION 62 
Over 70% of  women with ovarian cancer present with advanced disease, and  In 63 
usually have a very poor prognosis (1). Since Griffiths reported In 1975 (2) the association 64 
between reduced residual tumour load and improved survival rates  following debulking 65 
surgery,  primary surgery has been embedded in clinical practice as an essential , or even a 66 
mandatory,  therapeutic strategy.(3) However,  to date, there are still  no prospective 67 
randomised controlled trials available  proving that primary debulking surgery improves the 68 
prognosis of patients with advanced ovarian cancer.  69 
An alternative approach to primary debulking surgery,  is neoadjuvant chemotherapy, 70 
administered before attempting cytoreductive surgery. In  2010 the first randomised trial 71 
comparing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery  with 72 
primary debulking surgery (UDS) was published (4). This randomised EORTC study showed a 73 
similar overall and progression-free survival in women with FIGO (International Federation 74 
of Gynecology and Obstetrics) stage IIIC or IV ovarian cancer with both treatment strategies 75 
and a lower operative morbidity with NACT. These results were later confirmed in the 76 
randomised CHORUS trial (5) and resulted in the acceptance of NACT followed by IDS as an 77 
alternative for UDS in stage IIIC and IV ovarian cancer (6).  However, the selection of women 78 
with advanced ovarian cancer for NACT or UDS remains controversial (7).  79 
 In 2003, while the accrual of the EORTC study was ongoing but prior to the start of 80 
the CHORUS trial, we (EORTC/MRC) planned the current meta-analysis with the aim of 81 
analysing the long-term follow-up of both trials and to identify subgroups who might benefit  82 
more or less from NACT compared with UDS.  83 
  84 
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Materials and methods 85 
Eligibility and study design 86 
The eligibility criteria  and study design of the EORTC and CHORUS trials have 87 
previously been reported (4,5). In short, in the EORTC trial eligible women had biopsy proven 88 
Stage IIIC or IV invasive epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.  If 89 
a biopsy was not available, fine needle aspiration showing an adenocarcinoma was 90 
acceptable under the following conditions: presence of a pelvic (ovarian) mass; and presence 91 
of metastases of ≥ 2 cm (measured during diagnostic laparoscopy or laparotomy, and if not 92 
done, based on CT findings) outside the pelvis and a CA125 (KU/L)/CEA (ng/mL) ratio > 25. If 93 
the CA125/CEA ratio was less, investigations to exclude a gastrointestinal carcinoma were 94 
necessary before entry. In the CHORUS trial the inclusion criteria were similar, but women 95 
with apparent stage IIIA and IIIB were also eligible and  a histological or cytological 96 
confirmation of diagnosis was not required prior to randomization. In both trials 97 
randomization was to primary debulking surgery followed by at least 6 courses of platinum-98 
based chemotherapy, versus  three courses of neoadjuvant platinum-based chemotherapy 99 
followed by interval debulking surgery in all women  showing a response or stable disease, 100 
and then at least 3  nother courses of platinum based chemotherapy. In women randomised 101 
to primary debulking whose surgery was completed without optimal cytoreduction, interval 102 
debulking surgery was permitted if stable disease or response was documented and these 103 
patients were included for analyses in the primary debulking surgery arm. Randomisation 104 
was done for the EORTC trial at the EORTC Headquarters after stratification with a 105 
minimization technique to stratify for institution, method of biopsy (imaging-guided, 106 
laparoscopy, laparotomy, or fine needle aspiration), Stage IIIC or IV, and largest tumor size 107 
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(excluding ovaries) before surgery (less than 5, 5 – 10, 10 - 20 cm, or more than 20 cm). In 108 
the CHORUS trial the random assignment was performed centrally at the MRC CTU (Medical 109 
Research Council Clinical Trials Unit) using a minimisation method with a random element, 110 
and stratified the women according to randomizing Centre, largest radiological tumour size, 111 
clinical FIGO stage, and pre-specified chemotherapy regimen. 112 
 113 
Statistical design of the meta-analysis 114 
The meta-analysis was designed in 2003 by the CIs of the two trials (IV and SK) and 115 
members of the EORTC /MRC trials committees. The databases were examined and arranged 116 
to ensure appropriate information was collected to permit merging of both for the agreed 117 
meta-analysis. The women were followed until the data base lock. The meta-analysis was 118 
done based  on the individuals data, i.e. all data were merged instead of using only the 119 
summary data from each trial. The data were gathered at the EORTC Headquarters and 120 
analyzed in cooperation with the authors by the EORTC statistician (CC).  121 
The pooled dataset was estimated to contain between 800 to 900 events (deaths). 122 
Assuming a median overall survival (OS) of 3 years, this allows assessment  of  non-inferiority 123 
with a one-sided type I error of 0.05 and a power of 80% where inferiority is considered as 124 
an increase of more than 18-19% in hazard. Similarly, it would allow a 90% power in 125 
excluding a hazard increase of 22-23%.  Applying a two-sided test of superiority at 5%, the 126 
dataset would allow the  detection of  an 18% increase in hazard with 80% power.   127 
The analysis was performed according to the intent to treat policy: all randomized 128 
patients are included in the principal analysis, whatever their eligibility and evaluability 129 
status. A per-protocol population served as supportive analysis.  The definitions applied for 130 
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overall and progression-free survival are previously published. (4). Overall and progression-131 
free survival were estimated by the Kaplan-Meier method and overall survival compared via 132 
the log rank test. Multivariate time-to-event analysis was performed using a Cox 133 
proportional hazards model, with univariate screening followed by a multivariate stepwise 134 
variable selection procedure (8). All results were checked for homogeneity among the two 135 
studies and stratified per trial.  136 
The size of the largest metastases before randomization was measured in the EORTC 137 
study during diagnostic laparoscopy or laparotomy, and if not done, based on CT findings.  In  138 
the CHORUS trial these measurements were based on CT radiologic imaging only. Subgroup 139 
analyses according to the stratification factors which were common in both trials 140 
(randomizing Centre, largest tumor size (excluding ovaries) before surgery (less than 5, 5 – 141 
10, 10 - 20 cm, or more than 20 cm), and clinical FIGO stage) was planned.  142 
 143 
Results 144 
Patient characteristics 145 
 The patient data of both trials were updated and merged in one data base (data base 146 
lock EORTC June 6, 2015 and CHORUS May 20, 2015). 1220 patients were randomised. 147 
Median follow-up was 7.6 years (EORTC 9.2 and CHORUS 5.9 years).  The characteristics of 148 
the patients by study and study arm are summarised in Table 1 and 2, respectively. The 149 
baseline characteristics were well balanced between both treatment groups.  For details on 150 
size of residual tumor, residual tumor per country, type of surgery, number of courses and 151 
type of chemotherapy, and time to (re)initiation of chemotherapy we refer to the original 152 
papers. 153 
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Overall survival and progression-free survival 154 
 Overall survival (OS) was significantly better in the EORTC trial compared with the 155 
CHORUS trial (median, respectively 2.52 and 1.95 years; Hazard ratio (HR): 1.20, 95% 156 
Confidence Intervals (CI): 1.06-1.36; p = 0.004) (Figure 1), but progression-free survival (PFS) 157 
was similar (median respectively 0.96 and 0.93 years; HR 0.94, 95% CI: 0.84-1.06; not 158 
significant) (Supplemental file page 1).  159 
Overall survival (Figure 2) and progression-free survival (Supplemental file page 2) 160 
were similar for NACT and UDS (median respectively for OS 2.30 and 2.24 years, HR: 0.97, 161 
95% CI: 0.88-1.09; and for PFS respectively 0.97 and 0.93 years, HR: 0.98, 95% CI: 0.87-1.09; 162 
both not significant). Overall and progression-free survival per study and treatment arm are 163 
presented in the Supplemental file (page 3 and 4).  164 
Median overall survival was significantly different for Stage IV compared with Stage III 165 
and Stage II (median respectively, 1.94, 2.50 and 3.75 years; HR 2.75 and 1.92 for Stage III 166 
and IV versus stage II, p = 0.000; see Supplemental file page 5).  Overall survival was similar 167 
for NACT and UDS in Stage IIIC patients (median respectively, 2.56 and 2.37 years; HR: 1.04, 168 
95% CI: 0.90-1.21; not significant; Supplemental file page 6).  Progression-free survival was 169 
similar or NACT and UDS in Stage IIIC (median respectively, 1.02 and 0.97 years; HR: 1.05, 170 
95% CI: 0.92-1.21; not significant; Supplemental file page 7). However, in Stage IV NACT 171 
resulted in significantly better overall survival than UDS (Figure 3) (median respectively, 2.02 172 
and 1.77 years; HR: 0.76, 95% CI: 0.58-1.00, p = 0.048).  Also PFS was significantly better in 173 
Stage IV disease with NACT than with UDS (median respectively, 0.88 and 0.81 years; HR: 174 
0.77, 95% CI: 0.59-1.00, p = 0.050) (Supplemental file page 8).  175 
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Overall survival was significantly worse with increasing size of the largest metastasis 176 
at  the time of randomization (Supplemental file page 9).  In patients with Stage IIIC disease 177 
and a largest metastatic tumour size < 5 cm the progression-free survival was better with 178 
UDS than with NACT (Figure 4, respectively median 1.02 and 1.00; HR: 1.34, 95% CI: 1.04-179 
1.73; p=0.021), but the overall survival was not significantly different (median respectively, 180 
2.75 and 2.51 years; HR: 1.26, 95% CI: 0.96-1.65; not significant).  181 
 182 
Discussion 183 
 This  pre-planned meta-analysis of the updated data from  the EORTC and 184 
CHORUS trials on NACT versus UDS, confirms with long-term follow-up that NACT results in a 185 
similar overall survival compared with UDS in women with advanced ovarian carcinoma FIGO 186 
Stage IIIC and IV. In  addition it revealed   that progression-free and overall survival was 187 
significantly better with NACT than with UDS in patients diagnosed with Stage IV disease. 188 
However, women at Stage IIIC disease with the  largest metastatic tumour mass of less than 189 
5 cm had a significantly better progression-free survival with UDS.  For those with Stage III 190 
disease and larger sized metastatic disease, either approach resulted in the same overall 191 
survival. These findings indicate that when deciding on a treatment strategy, not only  192 
should the  risk of perioperative morbidity (6) and the possibility to debulk the patient to 193 
zero residual tumor (7) be taken into account, but also FIGO stage and the extent of the 194 
metastatic disease at presentation.  195 
 Though in both studies, a cytological diagnoses of malignancy was permitted, 196 
with the evolution of our knowledge regarding ovarian cancer disease subtypes, presently 197 
only histology can distinguish between high and low grade serous tumours [9]. This is 198 
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important, as low grade tumours are less susceptible to chemotherapeutic regimes and 199 
primary surgery is an important and preferential intervention in this group [10]. Thus to  200 
achieve a well-informed decision, histology should be obtained,  combined  with extensive 201 
radiological imaging.  Obtaining tissue may be by image guided biopsy, though a 202 
laparoscopic approach affords additional information on disease spread which can be 203 
included in the decision making process, besides ensuring sufficient tissue for diagnostic 204 
purposes. (11-13)   205 
 Applying the findings of this meta-analysis to the care of every woman with 206 
stage IIIC or IV ovarian cancer must always be combined with the clinical picture. For 207 
example,  the women in these studies had metastatic disease  with a high tumour burden at 208 
presentation, and many had a poor performance status.  But this clinical scenario is not 209 
uncommon and indeed improving outcomes for this population is as important (if not more 210 
so) than those who have  much better survival patterns. Accepting the caveats implicit 211 
within all clinical trials, the results  regarding the clinical management of stage IV disease, 212 
are derived from one of  the largest cohort of women with stage IV disease in phase III 213 
studies. With  this evidence, it can be recommended that NACT becomes the standard of 214 
care for this population, and primary surgery only used for the exceptional woman with 215 
Stage IV- selected on an individual basis.    216 
  217 
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Table 1. Baseline characteristics by study  218 
 
EORTC 
(n= 670) (%) 
Chorus 
(n=550) (%) 
TOTAL 
(n=1220) (%) 
Median Age (years) 62 65 63 
Largest metastatic tumor size (mm) 80 80 80 
CA125 at entry (KU/L) 1161 1016 1089 
WHO performance  
          0 
          1 
          2 
          3 
          Missing  
 
300 (44.8) 
284 (42.4) 
85 (12.5) 
0 (0) 
2 (0.3) 
 
171 (31.1) 
271 (49.3) 
102 (18.5) 
5 (0.9) 
1 (0.2) 
 
471 (38.6) 
555 (45.5) 
186 (15.2) 
5 (0.4) 
3 (0.2) 
FIGO stage 
          II 
          IIIA 
          IIIB 
          IIIC 
          IV 
          Missing 
 
0 (0) 
0 (0) 
1 (0.1) 
510 (76.1) 
158 (23.6) 
1 (0.1) 
 
19 (3.5) 
14 (2.5) 
21 (3.8) 
321 (58.4) 
72 (13.1) 
103 (18.7) 
 
19 (1.6) 
14 (1.1) 
22 (1.8) 
831 (68.1) 
230 (18.9) 
104 (8.5) 
    
 219 
 220 
221 
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Table 2. Baseline characteristics by allocated treatment  222 
 
UDS 
(n=612) (%) 
NACT 
(n=608) (%) 
TOTAL 
(n=1220) (%) 
Median Age (years) 63 64 63 
Largest metastatic tumor size (mm) 80 80 80 
CA125 at entry (KU/L) 1039 1137 1089 
WHO performance  
          0 
          1 
          2 
          3 
          Missing  
 
236 (38.6) 
279 (45.6) 
93 (15.2) 
1 (0.2) 
3 (0.5) 
 
235 (38.7) 
276 (45.4) 
 93 (15.3) 
4 (0.7) 
0 (0) 
 
471 (38.6) 
555 (45.5) 
186 (15.2) 
5 (0.4) 
3 (0.2) 
FIGO stage 
          II 
          IIIA 
          IIIB 
          IIIC 
          IV 
          Missing 
 
12 (2.0) 
7 (1.1) 
9 (1.5) 
433 (70.8) 
118 (19.3) 
33 (5.4) 
 
 7 (1.2) 
7 (1.2) 
13 (2.1) 
398 (65.5) 
112 (18.4) 
71 (11.7) 
 
19 (1.6) 
14 (1.1) 
22 (1.8) 
831 (68.1) 
230 (18.9) 
104 (8.5) 
    
  223 
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Figure 1. Overall survival according to study.  224 
  225 
(years)
0 2 4 6 8 10 12 14
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Study
602 670 395 185 102 42 14 3
451 550 265 110 37 7 0 0
EORTC 55971
MRC CHORUS
Overall survival
 
Overall Score test: p=0.004
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Figure 2. Overall survival according to treatment arm.  226 
 227 
  228 
(years)
0 2 4 6 8 10 12 14
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Treatment
528 612 322 149 74 27 7 3
525 608 338 146 65 22 7 0
Upfront debulking surgery
Neoadjuvant chemotherapy
Overall survival
 
Overall Score test stratified for Study: p=0.577
15 
 
Figure 3. Overall survival according to treatment arm in Stage IV patients.  229 
 230 
 231 
  232 
(years)
0 2 4 6 8 10 12
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Treatment
112 118 53 13 7 2 0
104 112 57 25 8 4 2
Upfront debulking surgery
Neoadjuvant chemotherapy
Overall survival
FIGO IV
Overall Score test stratified for Study: p=0.048
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Figure 4. Progression-free survival in 266 patients with FIGO IIIc and largest metastatic 233 
tumour size < 5 cm at entry.  234 
 235 
  236 
  237 
(years)
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